FAST-ACTING INSULIN ASPART AT HIGH DOSES IN INDIVIDUALS WITH TYPE 2 DIABETES

被引：0
|
作者：
Bowering, K. [1 ]
Harvey, J. [2 ]
Kolaczynski, J. [3 ]
Snyder, J. [4 ]
Bode, B. [5 ]
机构：
[1] Univ Alberta, Div Endocrinol & Metab, Edmonton, AB, Canada
[2] Bangor Univ, Wrexham Acad Unit, Bangor, Gwynedd, Wales
[3] Novo Nordisk Inc, Clin Dev Diabet & Obes, Plainsboro, NJ USA
[4] Novo Nordisk Inc, Clin Dev Med & Regulatory Affairs, Plainsboro, NJ USA
[5] Atlanta Diabet Associates, Atlanta, GA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
303
引用
收藏
页码：A133 / A133
页数：1
相关论文
共 50 条
  • [41] The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
    Leelarathna, Lalantha
    Ashley, Donna
    Fidler, Carrie
    Parekh, Witesh
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (07) : 187 - 197
  • [42] Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart
    Pieber, T. R.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    DIABETOLOGIA, 2017, 60 : S315 - S315
  • [43] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: Comparison with insulin aspart in onset 1
    Twigg, Stephen
    Mathieu, Chantal
    Bode, Bruce
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 63 - 63
  • [44] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1
    Mathieu, C.
    Bode, B.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A.
    Russell-Jones, D.
    DIABETOLOGIA, 2017, 60 : S314 - S314
  • [45] ONSET 1: EFFICACY AND SAFETY OF MEALTIME FAST-ACTING INSULIN ASPART VERSUS INSULIN ASPART AFTER 52 WEEKS
    Bode, B.
    Mathieu, C.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A. B.
    Russell-Jones, D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A29
  • [46] Efficacy and Safety of Fast-Acting Insulin Aspart Are Maintained over 52 Weeks: Comparison with Insulin Aspart in Onset 1
    Mathieu, Chantal
    Bode, Bruce W.
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    DIABETES, 2017, 66 : A258 - A258
  • [47] Investigating the safety and glycaemic control of fast-acting insulin aspart with a closed-loop delivery system in adults with type 1 diabetes
    Russell, S. J.
    Balliro, C. A.
    Ekelund, M.
    El-Khatib, F.
    Graungaard, T.
    Jafri, R.
    Rathor, N.
    Sherwood, J.
    Damiano, E. R.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S346 - S346
  • [48] A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
    Tim Heise
    Thomas R. Pieber
    Thomas Danne
    Lars Erichsen
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 551 - 559
  • [49] Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements
    Lane, Wendy
    Ekelund, Magnus
    Thorisdottir, Olof
    Jodar, Esteban
    Oviedo, Alejandra
    Rathor, Naveen
    Senior, Peter
    Sesti, Giorgio
    Franek, Edward
    DIABETES, 2020, 69
  • [50] INVESTIGATING THE SAFETY AND GLYCAEMIC CONTROL OF FAST-ACTING INSULIN ASPART WITH A CLOSED-LOOP DELIVERY SYSTEM IN ADULTS WITH TYPE 1 DIABETES
    Russell, S.
    Balliro, C.
    Ekelund, M.
    El-Khatib, F.
    Graungaard, T.
    Jafri, R.
    Rathor, N.
    Sherwood, J.
    Damiano, E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A37 - A37
12345